NCT04318418View on ClinicalTrials.gov

ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19

CompletedOBSERVATIONAL
Enrollment

3,400

Participants

Timeline

Start Date

March 23, 2020

Primary Completion Date

May 10, 2020

Study Completion Date

June 30, 2020

Conditions
COVID-19
Trial Locations (1)

86077

IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli

All Listed Sponsors
lead

Neuromed IRCCS

OTHER

NCT04318418 - ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19 | Biotech Hunter | Biotech Hunter